All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IO102,IO103,Nivolumab
Therapeutic Area: Oncology Product Name: IO102
Highest Development Status: Phase I/ Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2020
Details:
According to the abstract, the combination of IO102 and IO103 vaccines and nivolumab was shown to be safe with encouraging early efficacy data; an overall response rate (ORR) of 79 percent was reached and 45 percent of patients achieved a complete response.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Endovion,Fluorouracil,Leucovorin Calcium
Therapeutic Area: Oncology Product Name: SCO-101
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 20, 2020
Details:
First part of the trial aimed at establishing the safety, tolerability and Maximum Tolerated Dose of SCO-101 in combination with FOLFIRI. One patient has obtained stable disease, according to RECIST version 1.1 at 8 weeks after starting the treatment.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Epcoritamab
Therapeutic Area: Oncology Product Name: DuoBody-CD3xCD20
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $3,150.0 million Upfront Cash: $750.0 million
Deal Type: Collaboration June 10, 2020
Details:
The companies will partner to develop Genmab's next-generation bispecific antibody programs, epcoritamab (DuoBody®-CD3xCD20), DuoHexaBody®-CD37 and DuoBody-CD3x5T4.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Epcoritamab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
A list of accepted Industry-sponsored abstracts featured at the congress includes two abstracts on epcoritamab (DuoBody®-CD3xCD20), one on HexaBody®-CD38, one on DuoHexaBody®-CD37 and four daratumumab abstracts.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Epcoritamab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2020
Details:
The presentation will demonstrate continued solid progress in Genmab's development of epcoritamab (DuoBody-CD3xCD20).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SCO-101
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2020
Details:
Phase II trial of SCO-101 treats a critical condition with no satisfactory treatment choice, thus Scandion has agreed to continue the research of colorectal cancer with patients resistant to FOLFIRI.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IO102,Pembrolizumab,Carboplatin
Therapeutic Area: Oncology Product Name: IO102
Highest Development Status: Phase I/ Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 25, 2020
Details:
The Safety Monitoring Committee has recommended to continue the trial without modifications as the futility boundary was successfully passed.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
